Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(1):6-10
DOI: 10.5428/pcar20180102
Preparation of polycationic composites delivering plasmid of tumor necrosis factor related apoptosis-inducing ligand and its in vitro anti-hepatoma activity
1. XU YouFa 1(1.Depatment of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China yjxuyf@163.com)
2. 2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China )
3. CHENG Dan2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China )
4. FU ZhiQin1(1.Depatment of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China )
5. 2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China )
6. LIU Ying2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China )
7. WU Xin2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China )
8. CHEN JianMing1(1.Depatment of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China yjcjm@163.com)
9. 2(2.Depatment of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China yjcjm@163.com)
ABSTRACT  Objective: To condense plasmid of tumor necrosis factor related apoptosis-inducing ligand(pTRAIL) with novel cationic carriers,so as to solve the problems of low cellular uptake and easy degradation of gene drugs,and subsequently to investigate in vitro anti-hepatoma activity of the nanocomposites.Methods: The particle size and zeta potential were determined by Zeta sizer.Agarose gel electrophoresis was applied to evaluate the capability of condensing pTRAIL of stearyl polypeptide(SHR) and stearyl polypeptide polymer(SHRss).The cellular uptake of SHR/pTRAIL and SHRss/pTRAIL by hepatoma cells was evaluated by laser confocal microscopy.The cytotoxicity of carriers and the anti-hepatoma activity of nanocomposites were determined by CCK-8 method.Results: The biocompatible SHR and SHRss could condense pTRAIL to form stable nanocomposites.The smallest particle sizes of SHR/pTRAIL and SHRss/pTRAIL were (306.22±31.64) and (184.41±25.16) nm,respectively,when N/P was 10.Crosslinked SHRss could significantly enhance condensation capability,increase cellular uptake and improve anti-hepatoma activity of pTRAIL.After incubation with SHR/pTRAIL and SHRss/pTRAIL for 24 h,the HepG2 cell viability was (82.58±9.46)% and (65.39±5.43)%,respectively.Conclusion: Low-toxic and highly efficient SHRss/pTRAIL might be used as a novel gene transporter for the treatment of hepatoma.
Welcome to PCAR! You are the number 410 reader of this article!
Please cite this article as:
XU YouFa 1,2,CHENG Dan2,FU ZhiQin1,2,LIU Ying2,WU Xin2,CHEN JianMing1,2,. Preparation of polycationic composites delivering plasmid of tumor necrosis factor related apoptosis-inducing ligand and its in vitro anti-hepatoma activity[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(1): 6-10.
References:
1. Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2. Naldini L.Gene therapy returns to centre stage[J].Nature,2015,526(7573):351-360.
3. Naoum G E,Tawadros F,Farooqi A A,et al.Role of nanotechnology and gene delivery systems in TRAIL-based therapies[J].Ecancermedicalscience,2016,10:660.
4. de Miguel D,Lemke J,Anel A,et al.Onto better TRAILs for cancer treatment[J].Cell Death Differ,2016,23(5):733-747.
5. Piras-Straub K,Khairzada K,Trippler M,et al.TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth,recurrence and survival[J].Int J Cancer,2015,136(4):E154-E160.
6. Nojiri K,Sugimoto K,Shiraki K,et al.Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma[J].Int J Oncol,2013,42(1):101-108.
7. Tai Z,Wang X,Tian J,et al.Biodegradable stearylated peptide with internal disulfide bonds for efficient delivery of siRNA in vitro and in vivo[J].Biomacromolecules,2015,16(4):1119-1130.
8. Collins M,Thrasher A.Gene therapy:progress and predictions[J].Proc Biol Sci,2015,282(1821):20143003.
9. Ginn S L,Alexander I E,Edelstein M L,et al.Gene therapy clinical trials worldwide to 2012-an update.[J].J Gene Med,2013,15(2):65-77.
10. Doi K,Takeuchi Y.Gene therapy using retrovirus vectors:vector development and biosafety at clinical trials[J].Uirusu,2015,65(1):27-36.
11. Bottai G,Truffi M,Corsi F,et al.Progress in nonviral gene therapy for breast cancer and what comes next?[J].Expert Opin Biol Ther,2017,17(5):595-611.
12. Chandana T,Venkatesh Y P.Occurrence,functions and biological significance of arginine-rich proteins[J].Curr Protein Pept Sci,2016,17(5):507-516.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口